Pacific Biosciences of California pushes whole genome sequencing to transform newborn care

Pacific Biosciences of California pushes whole genome sequencing to transform newborn care
Pacific Biosciences targets newborn genomics

Pacific Biosciences of California is advocating for whole genome sequencing (WGS) to play a pivotal role in redefining newborn medical care.

The company points to advances in its WGS technology, which could offer a lifelong genomic record and help end the lengthy diagnostic odyssey faced by many families. By moving beyond traditional heel prick tests, Pacific Biosciences of California suggests that comprehensive sequencing can enable earlier and more proactive medical intervention, ultimately supporting better health outcomes for newborns.

Pacific Biosciences of California has recently advanced disease research by using its HiFi WGS platform to improve detection of structural variants across diverse populations, according to a previous announcement. The company has also launched PRISM San Diego, introducing SPRQ-Nx chemistry and the Vega system to the life sciences sector, as detailed in an earlier launch update. These efforts reflect PacBio's ongoing development of sequencing technologies for medical applications.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.